AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-132059409/headaches-continue-big-drug.html" title="Facts and information about Headaches Continue For Big Drug Firms, And No End In Sight; Maybe It's Time For A Change; Experts: Big pharma needs a new prescription when it comes to focus, research.(HEALTH & MEDICINE)">Headaches Continue For Big Drug Firms, And No End In Sight; Maybe It's Time For A Change; Experts: Big pharma needs a new prescription when it comes to focus, research.(HEALTH & MEDICINE)</a>
Close
Set up an RSS feed that alerts you when new articles from Investor's Business Daily are available.
Frequently asked questions about RSS feeds
Headaches Continue For Big Drug Firms, And No End In Sight; Maybe It's Time For A Change; Experts: Big pharma needs a new prescription when it comes to focus, research.(HEALTH & MEDICINE)
Byline: PETER BENESH
Problems facing big drug makers these days have been well documented. They range from deadly medicines to questionable research practices.
It's tempting to view the industry's current woes as temporary blips that will fade away soon enough.
Don't bet on it. Industry watchers say problems facing big pharma have been a long time in the making.
Go back a half-decade and you'll see a steady slide in the stock prices of major players such as Merck, Glaxo SmithKline, Eli Lilly, Bristol Myers Squibb, Schering Plough and Pfizer.
Wanted: R&D
The malaise in big pharma runs deep. It's the result of dysfunctional corporate cultural, shortsightedness, regulatory pressure and pressure from Wall Street, experts say.
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- Big drug firms focus on San Diego: Pfizer, Novartis, and others commit major...
- Magazine article from: San Diego Business Journal Webb, Marion May 12, 2003 700+ words
...They provide the fuel that makes for big drug discoveries. Joseph Panetta, president...Pfizer's Viagra, productivity in big drug labs has substantially fallen. Computerized...sophisticated biotechnology tools that drug firms use to cut the cost-and-time...
- Doctors told to be wary of big drug firms.
- News wire article from: Asia Africa Intelligence Wire June 17, 2005 700+ words
...the forum said. The enforcement would allow international drug firms to hold patent rights for up to 25 years after registration...Drug Control Division. Most of them were produced by giant drug firms in the US and Europe. Chernporn Tengamnuay, president of...
- Healthy future seen for big drug firms.
- Newspaper article from: The Milwaukee Journal Sentinel (Milwaukee, Wisconsin) (via Knight-Ridder/Tribune Business News) August 1, 2005 700+ words
...are a lot of reasons to hesitate before buying the stocks of big drug companies. But one local value-oriented money manager says...rise in the Standard & Poor's 500 index. Many of the big drug company names are down 40 percent to 70 percent from their...
- Big drug firms form alliances.
- News wire article from: Asia Africa Intelligence Wire August 2, 2004 700+ words
(From Chemical Business NewsBase - Chemical and Engineering News) Several drug development pacts were announced last week, including an agreement between Lexicon Genetics and Takeda Pharmaceutical to develop new drugs for the treatment of high blood pressure. Takeda will be responsible for
- INDIA: BIG DRUG FIRMS FIGHT TO KEEP THEIR ADVANTAGE ON GENERICS.
- News wire article from: Interpress Service February 13, 2007 700+ words
by Keya Acharya BANGALORE, Feb. 13, 2007 (IPS/GIN) -- As health groups await the outcome of Swiss pharmaceutical giant Novartis AG's challenge to India's patent law, a campaign is building up against a parallel move to obtain "data exclusivity" on clinical trial data submitted to government for
- Families fund a search for rare disease's cure, because big drug firms don't.
- Newspaper article from: Chicago Tribune (Chicago, IL) September 26, 2004 700+ words
Byline: Jon Van Sep. 26--Large drug companies relish male impotence, high blood pressure and arthritis because the millions of people with those afflictions are a lucrative market. But with a genetic ailment that strikes only one child in 6,000, the prospects for profit are slim. And even if a
- Critics call effort to aid poor a tool of big drug firms.
- Newspaper article from: Salt Lake Tribune (Salt Lake City, UT) September 26, 2006 700+ words
Byline: Kirsten Stewart Sep. 26--It's billed as a grass-roots effort to improve patient access to quality health care. But a new coalition headed by Duane Bourdeaux, a former legislator turned crusader for the poor, has members of Utah's advocacy community distancing themselves from what they're
- FDA's Thumbs Down On Sales Of Statins Is Familiar Refrain; No Over-The-Counter...
- Magazine article from: Investor's Business Daily January 31, 2005 700+ words
Byline: AMY REEVES With the cost of developing a single drug running upward of $800 million, it's no wonder drug makers want to squeeze every last drop of revenue out of their products. That's one reason some have spent the last decade pestering the Food and Drug Administration to approve
- Drug Firms Plumb For Answers To Clogged Product Pipeline; No Blockbusters On...
- Magazine article from: Investor's Business Daily October 11, 2004 700+ words
...welcome the attention, however. Big drug makers are perceived by some startups...serving, Goodall says. His solution? Big drug firms should ask themselves how they can...acceptable to potential partners. Big drug makers also need to come to terms...
- Drug Firms Weigh On Health Sector; But Some Yields Good; Fund managers soured...
- Magazine article from: Investor's Business Daily December 28, 2004 700+ words
...segments of health care. Big drug makers have too few promising...also be hurt more if a big drug maker loses a key patent...disorder. Lilly sued three drug firms in federal court for...several -- including drug firms -- are paying attractive...